- United Therapeutics Corp (NASDAQ:UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with chronic obstructive pulmonary disease.
- The company terminated the study based on a recommendation of the study’s independent Data Safety Monitoring Committee (DSMC), following a routine safety and efficacy analysis conducted by the DSMC.
- The company will review the study’s available data and plan to share the results with the scientific community.
- According to clinicaltrials.gov, the trial was expected to conclude in 2024.
- In its Q2 earnings release, United Therapeutics disclosed it decided to trigger a pre-specified transition and convert the PERFECT study from a crossover study into a single treatment period of 12 weeks.
- Price Action: UTHR shares are down 3.44% at $209.42 on the last check Tuesday.
CUEX Metal AG And Caravelle International Group Sign Innovative Manganese Ore Purchase Agreement To Advance Wood Drying Business; Caravelle Expects To Earn Close To $400M-500M Annually Through The Partnership With CUEX; Caravelle’s Total Revenues Are E…
Caravelle International Group (NASDAQ:CACO), a leading global marine technology group of companies, today announced the signing of an innovative manganese ore sourcing agreement with CUEX Metal AG ("CUEX"), a leading
